Drug Deal Disclosure Act

The Drug Deal Disclosure Act requires the Department of Health and Human Services to publicly release specific records regarding agreements between the federal government and major drug manufacturers starting in 2025. This law mandates the disclosure of contracts that include provisions such as reduced drug prices based on international rates, direct-to-consumer sales discounts, duty exemptions, and special treatment for Medicare programs. While the bill allows for the redaction of confidential pricing details, it prohibits withholding information based on political sensitivity or reputational harm and requires a detailed justification for any redactions. Additionally, the act mandates reports to Congress and independent analysis from the Congressional Budget Office and the Government Accountability Office to evaluate the economic and budgetary impacts of these agreements.